eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
1/2012
vol. 37
 
Share:
Share:
abstract:

Experimental immunology
Anti-Toll-like receptor 2 antibody, T2.1, reduces tumor necrosis factor α and interleukin-6 release and inhibits nuclear factor κB expression in bacterial lipoprotein stimulated THP-1 cells

Min Huang
,
Jing Zhou
,
Liqing Bi
,
Qian Zhang
,
Suming Zhou

(Centr Eur J Immunol 2012; 37 (1): 6-10)
Online publish date: 2012/03/29
View full text Get citation
 
This study analyzed the effects of a blocking anti-Toll-like receptor 2 (TLR2) antibody (T2.1) on TLR2 signaling and inflammatory cytokine production by bacterial lipoprotein (BLP) stimulated THP-1 cells. Cells were treated sequentially with anti-TLR2 antibody and BLP (A + B) or in the reverse order (B + A), or directly stimulated with BLP (B). Blank and isotype control groups were included. Tumor necrosis factor α (TNF-α) and interleukin-6 (IL-6) concentrations were measured by ELISA. Expression of nuclear factor κB (NF-κB), TLR2 and myeloid differentiation factor 88 (MyD88) was analyzed by Western Blot. Significantly higher expression of TNF-α, IL-6 and NF-κB was detected in all groups compared with the blank control (P < 0.05), although expression was significantly lower in A + B and B + A compared with the isotype control and B (P > 0.05). However, no significant differences were detected in TLR2 and MyD88 expression among these groups (P > 0.05). These data demonstrated that anti-TLR2 antibody significantly reduced TNF-α, IL-6 and NF-κB expression by BLP-stimulated THP-1 cells, thus indicating the protective value of this antibody in vivo.
keywords:

anti-TLR2 antibody, BLP, NF-κB, TNF-α, IL-6


Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.